Cinclus Pharma: Linaprazan glurate receives approval in China - Redeye

Redeye leaves a comment following Cinclus’ announcement of linaprazan glurate having received market approval in China. We are encouraged by this important milestone and see it as a strong testament to the clinical data and potential health-economic value of the treatment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1063404/cinclus-pharma-linaprazan-glurate-receives-china-approval?utm_source=finwire&utm_medium=RSS